Monitoring Disease Activity: How and When?

Kang-Moon Lee

doi:10.4166/kjg.2018.71.2.69

Journal List > Korean J Gastroenterol > v.71(2) > 1007770

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee: Monitoring Disease Activity: How and When?

Special Review

Advances in IBD Management: Where Are We Now and Where Are We Headed for?

The Korean Journal of Gastroenterology 2018; 71(2): 69-73.

Published online: 23 February 2018

DOI: https://doi.org/10.4166/kjg.2018.71.2.69

Monitoring Disease Activity: How and When?

Kang-Moon Lee

Division of Gastroenterology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.

Correspondence to: Kang-Moon Lee, Division of Gastroenterology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, 93 Jungbu-daero, Paldal-gu, Suwon 16247, Korea. Tel: +82-31-249-8151, Fax: +82-31-253-8898, drmaloman@catholic.ac.kr

Received 5 February 2018 Revised 8 February 2018 Accepted 9 February 2018

Korean Society of Gastroenterology

(open-access):

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Inflammatory bowel disease (IBD) is a chronic, idiopathic inflammatory disease of gastrointestinal tract with waxing and waning clinical course, which may lead to irreversible bowel damage and a loss of bowel function. Cumulative intestinal damage results in complications such as stricture or fistulae, and eventually a large number of IBD patients undergo surgery. Notably, even during remission period (no clinical symptoms), subclinical inflammation often persists and the disease continues to progress. Therefore, the therapeutic target of IBD has been evolving from symptomatic control to mucosal healing to prevent structural intestinal damage. To achieve therapeutic goals in IBD, it is important to optimize therapy according to disease severity and response to treatment. Therefore, monitoring disease activity is recommended throughout the disease course of IBD. Especially strategies to monitor disease beyond symptoms through endoscopy, laboratory markers, and imaging is required.

Keywords: Inflammatory bowel disease, Monitoring, Disease activity, Crohn disease, Ulcerative colitis

Figures and Tables

Table 1

Monitoring Tools for Inflammatory Bowel Disease

CBC, complete blood count; LFT, liver function test; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; MR, magnetic resonance; CT, computed tomography.

Notes

^{Financial support} None.

^{Conflict of interest} None.

References

1. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002; 8:244–250.

2. Solberg IC, Vatn MH, Høie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007; 5:1430–1438.

3. Pariente B, Cosnes J, Danese S, et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011; 17:1415–1422.

4. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015; 110:1324–1338.

5. Choi CH, Moon W, Kim YS, et al. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017; 15:7–37.

6. Park JJ, Yang SK, Ye BD, et al. Second Korean guidelines for the management of Crohn's disease. Intest Res. 2017; 15:38–67.

7. Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017; 11:3–25.

8. Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017; 11:769–784.

9. Ye BD, Jang BI, Jeen YT, et al. Diagnostic guideline of Crohn's disease. Korean J Gastroenterol. 2009; 53:161–176.

10. Wei SC. Could fecal calprotectin enter mainstream use for diagnosing and monitoring inflammatory bowel disease? Intest Res. 2016; 14:293–294.

11. Kato J, Hiraoka S, Nakarai A, Takashima S, Inokuchi T, Ichinose M. Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin? Intest Res. 2016; 14:5–14.

12. Choi CH, Jung SA, Lee BI, et al. Diagnostic guideline of ulcerative colitis. Korean J Gastroenterol. 2009; 53:145–160.

13. Lee SS, Ha HK, Yang SK, et al. CT of prominent pericolic or perienteric vasculature in patients with Crohn's disease: correlation with clinical disease activity and findings on barium studies. AJR Am J Roentgenol. 2002; 179:1029–1036.

14. Sauter B, Beglinger C, Girardin M, et al. Monitoring disease activity and progression in Crohn's disease. A Swiss perspective on the IBD ahead ‘optimised monitoring’ recommendations. Digestion. 2014; 89:299–309.

15. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009; 15:1295–1301.

16. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011; 141:1194–1201.

17. Christensen B, Rubin DT. Understanding endoscopic disease activity in IBD: how to incorporate it into practice. Curr Gastroenterol Rep. 2016; 18:5.

18. Jürgens M, Mahachie John JM, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011; 9:421–427.e1.

19. Kiss LS, Szamosi T, Molnar T, et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther. 2011; 34:911–922.

20. Røseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004; 39:1017–1020.

21. Sipponen T, Savilahti E, Kärkkäinen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2008; 14:1392–1398.

22. Arai T, Takeuchi K, Miyamura M, et al. Level of fecal calprotectin correlates with severity of small bowel Crohn's disease, measured by balloon-assisted enteroscopy and computed tomography enterography. Clin Gastroenterol Hepatol. 2017; 15:56–62.

23. Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014; 13:24–30.

24. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362:1383–1395.

25. D'Aoust J, Battat R, Bessissow T. Management of inflammatory bowel disease with Clostridium difficile infection. World J Gastroenterol. 2017; 23:4986–5003.

26. Bitton A, Buie D, Enns R, et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012; 107:179–194. author reply 195.

27. Papay P, Ignjatovic A, Karmiris K, et al. Optimising monitoring in the management of Crohn's disease: a physician's perspective. J Crohns Colitis. 2013; 7:653–669.

28. Reinisch W, Wang Y, Oddens BJ, Link R. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther. 2012; 35:568–576.

29. Kiss LS, Papp M, Lovasz BD, et al. High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification? Inflamm Bowel Dis. 2012; 18:1647–1654.

30. Molander P, af Björkesten CG, Mustonen H, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis. 2012; 18:2011–2017.

31. Yamamoto T, Shimoyama T, Matsumoto K. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis. Aliment Pharmacol Ther. 2015; 42:549–558.

32. De Vos M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013; 19:2111–2117.

33. Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology. 2015; 148:639–651.e28.

34. Terdiman JP. Prevention of postoperative recurrence in Crohn's disease. Clin Gastroenterol Hepatol. 2008; 6:616–620.

35. Lee YW, Lee KM, Chung WC, Paik CN, Sung HJ, Oh YS. Clinical and endoscopic recurrence after surgical resection in patients with Crohn's disease. Intest Res. 2014; 12:117–123.

36. Kim YS. What is the important issue to prevent the postoperative Crohn's disease? Intest Res. 2014; 12:85–86.

37. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990; 99:956–963.

38. De Cruz P, Kamm MA, Hamilton AL, et al. Crohn's disease management after intestinal resection: a randomised trial. Lancet. 2015; 385:1406–1417.

39. Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology. 2015; 148:938–947.e1.

40. Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Serial monitoring of faecal calprotectin for the assessment of endoscopic recurrence in asymptomatic patients after ileocolonic resection for Crohn's disease: a long-term prospective study. Therap Adv Gastroenterol. 2016; 9:664–670.

41. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018; 390:2779–2789.

TOOLS

Similar articles